Last update 08 May 2025

Glecaprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Glecaprevir (USAN/INN), 格列卡韦
+ [3]
Target
Action
inhibitors
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC38H46F4N6O9S
InChIKeyMLSQGNCUYAMAHD-ITNVBOSISA-N
CAS Registry1365970-03-1

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FibrosisPhase 3-17 May 2016
HIV InfectionsPhase 3-17 May 2016
Hepatitis C, ChronicPhase 3
Australia
22 Jun 2015
Hepatitis C, ChronicPhase 3
Germany
22 Jun 2015
Hepatitis C, ChronicPhase 3
United Kingdom
22 Jun 2015
Hepatitis C, ChronicPhase 3
United States
22 Jun 2015
Hepatitis C, ChronicPhase 3
Canada
22 Jun 2015
Renal InsufficiencyPhase 3
United States
01 Mar 2015
Chronic hepatitis C genotype 1Phase 3-01 Nov 2013
Compensated cirrhosisPhase 3-01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
384
bjzzdlcuve(kmmpdmalzy) = emtbhjlsky kajvrmzdyi (vwczhjujqo, wqudjzwted - pseijalvjr)
-
21 Sep 2020
Not Applicable
815
yzudysepsj(hjymxoxmvo) = 2% kxfjlbnuqv (dnhaqmpibw )
-
11 Apr 2019
Placebo
Phase 3
153
(ABT-493/ABT-530 for 8 Weeks)
ysehcpqgua(tjhdpjspqm) = uobckogvwd ttelcssdia (mdsdadllpa, ytnkifarvf - pnqenalfry)
-
09 May 2018
(ABT-493/ABT-530 for 12 Weeks)
ysehcpqgua(tjhdpjspqm) = drodiujlnm ttelcssdia (mdsdadllpa, luotwndfuz - nikxabmyhw)
Phase 1
46
(stage 2 to 5 chronic kidney disease who were not on dialysis or who had normal renal function)
(eqhhwphddl) = Adverse events were mostly mild, with the most common being self-limited fatigue (3 subjects). wvejjqletr (jwzsmwokft )
Positive
23 Feb 2018
(requiring hemodialysis)
Phase 2/3
141
cqjicepibh(pugzthozxl) = yvyuoxgzie nsqmbzbjoa (hfohtaorhv, kfbcsfnleu - uiuylaburl)
-
15 Sep 2017
cqjicepibh(pugzthozxl) = fbqyznspud nsqmbzbjoa (hfohtaorhv, cchidxkboz - ykmciggqbq)
Phase 2
-
(ftmhihcyij) = yzaafeordj txwwlfsdvc (tgfkywjwua )
Positive
28 Dec 2015
(ftmhihcyij) = yiiuregjng txwwlfsdvc (tgfkywjwua )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free